Article Text

Download PDFPDF

PO.7.146 Sensitivity analysis of EQ-5D-3L index scores in relation to discriminative and known-groups validity in systemic lupus erythematosus
  1. N Hua1,
  2. A Gomez1,
  3. J Lindblom1,
  4. G Von Perner2,
  5. Y Enman1,
  6. M Regardt3,
  7. E Heintz4,
  8. S Emamikia1,
  9. D Grannas5 and
  10. I Parodis1
  1. 1Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital ~ Stockholm ~ Sweden
  2. 2Swedish Rheumatism Association ~ Stockholm ~ Sweden
  3. 3Department of Neurobiology, Care Sciences and Society, Karolinska Institutet ~ Stockholm ~ Sweden
  4. 4Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet ~ Stockholm ~ Sweden
  5. 5Divison of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet ~ Stockholm ~ Sweden


Purpose To investigate the ability of different EQ-5D-3L index scores to discriminate between verum drug and placebo (discriminant validity) as well as between responders and non-responders (known-groups validity) in the SLE patient population of two phase III clinical trials of belimumab.

Methods Data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials (N = 1684), which both showed superiority of belimumab to placebo, were utilised. Responders were defined as SLE Responder Index 4 (SRI-4) achievers at week 52. The Pearson’s χ2 and Mann-Whitney U tests were used for comparisons, and logistic regression analysis was used for adjustments for confounders and assessment of independence.

Results While full health state (FHS; EQ-5D index score 1) showed the best ability to discriminate between belimumab and placebo (adjusted OR: 1.47; 95% CI:1.1–2.0; P=0.008) and between SRI-4 responders and non-responders (adjusted OR: 3.47; 95% CI: 1.3–11.0; P=0.020), the discriminative ability of EQ-5D index scores 0.800 or more reached statistical significance for both discriminant validity (adjusted OR: 1.29; 95% CI: 1.0–1.6; P=0.036) and known-groups validity (adjusted OR: 3.08; 95% CI: 1.2–9.7; P=0.034).

Conclusions Overall, higher EQ-5D index scores were associated with increasing ability to discriminate between belimumab and placebo, and between responders and non-responders. EQ-5D index scores less stringent than FHS may be clinically relevant treatment targets in patients with SLE, introducing the concept of EQ-5D adequate health state.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.